This content is machine translated Asthma: focus on type 2 inflammation Remission as a new therapeutic goal A paradigm shift is emerging in the management of asthma, where the aim is not only asthma control but also remission. It has been shown that this ambitious goal can...…
View Post 5 min This content is machine translated Severe asthma Check diagnosis and initiate phenotype-based therapy In patients with inadequately controlled asthma under maximum inhalation therapy, it should be critically questioned whether the diagnosis of asthma is really present and whether all treatment measures are being…
View Post 8 min This content is machine translated Rare skin diseases Patience and expertise are required for bullous pemphigoid Direct and indirect immunofluorescence are still the gold standard for the detection of specific antibodies and autoantibodies in bullous pemphigoid. Highly effective topical steroids or systemic corticosteroids are recommended as…
View Post 4 min This content is machine translated Bullous pemphigoid Updated European expert guideline published The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) recently issued new recommendations for the treatment of bullous pemphigoid. The consensus expert opinion is based…
View Post 4 min This content is machine translated Chronic spontaneous urticaria When antihistamines are not enough – ligelizumab soon available in addition to omalizumab? The biologic omalizumab has empirically well-documented efficacy and safety and is considered the treatment of choice in international guidelines for cases of chronic spontaneous urticaria with inadequate response to antihistamines.…
View Post 4 min This content is machine translated Chronic spontaneous urticaria FcεRI as a potential biomarker for treatment response to omalizumab. In patients with chronic spontaneous urticaria, high baseline serum FcεRI levels may be a predictor of response to omalizumab treatment. This is the conclusion of a study presented at the…
View Post 4 min This content is machine translated Perspectives for CRSwNP therapy. New approaches in the pipeline Currently, there are two approved biologics for the treatment of CRS and polyposis nasi: dupilumab and omalizumab. However, several other therapeutic options are currently in development, some of which are…
View Post 5 min This content is machine translated Chronic urticaria In which cases do the guidelines recommend omalizumab? According to the guidelines, omalizumab can be used if therapy with dosed H1 antihistamines does not lead to sufficient relief of symptoms. There is ample evidence of efficacy for this…
View Post 5 min This content is machine translated Congress European Academy of Allergy and Clinical Immunology, Munich, Germany News on the pathogenesis and therapy of chronic urticaria Although chronic urticaria is not considered an allergic disease, IgE antibodies play an important role. Anti-IgE therapy with omalizumab is repositioned in the updated international guideline. Also, why not all…
View Post 8 min This content is machine translated Allergic diseases Symptomatic therapy is fast and well effective The treatment of allergic diseases, regardless of the triggering source resp. of the agent, is based on three principles: avoidance, symptomatic treatment, and allergen-specific treatments such as specific immunotherapy. Most…
